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Abstract
Background: Human papillomavirus (HPV) L1 capsid proteins can self-assemble into pentamers
(capsomeres) that are immunogenic and can elicit neutralizing antibodies. Structural modelling of
L1 inter-pentameric interactions predicts that helix 4 (h4) of each of the five L1 monomers project
laterally and outwards from the pentamer. We sought to utilize HPV L1 capsomeres as a vaccine
platform by engineering heterologous epitopes within L1 derivatives deleted for h4 domain.
Results: We used baculovirus – infected Trichoplusia ni cells and ultracentrifugation to synthesize
and purify three 16L1 derivatives: one bearing a short deletion (amino acids 404–436)
encompassing the h4 domain, and two others, each bearing a conserved neutralizing epitope of the
human respiratory syncytial virus (RSV) fusion (F) protein (residues 255–278 and 423–436) that
was substituted for the deleted L1 h4 domain residues. Each of the three capsomere derivatives
was recognized by anti-L1 antibodies, while two bearing the RSV F-derived moieties were
recognized by anti-RSV F antibodies. All three L1 derivatives formed ring-like structures that were
similar in morphology and size to those described for native 16L1 capsomeres. When injected into
mice, each of the capsomere derivatives was immunogenic with respect to L1 protein, and
immunization with chimeric L1-RSV F pentamers resulted in RSV non-neutralizing antisera that
recognized purified RSV F protein in immunoblots.
Conclusion: HPV L1 monomers bearing heterologous epitopes within the L1 h4 region can self-
assemble into capsomeres that elicit antibody response against such non-HPV encoded epitopes.
Thus, the L1 h4 region can function as a novel antigen display site within the L1 pentamer, which
in turn may serve as a potential vaccine template.
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Background
Human papillomaviruses (HPVs) are non-enveloped
DNA oncogenic viruses that cause significant burden of
disease, including cervical dysplasia and cancer [1]. The
major structural component of the HPV virion is the L1
viral capsid protein that can spontaneously form pentam-
ers (capsomeres) [2,3]. Such L1 oligomers can then self-
assemble into one of two virus-like particles (VLPs): a
spherical lattice structure of T = 7 symmetry group that is
morphologically indistinguishable from native HPV viri-
ons, or a smaller T = 1 particle that is comprised of 12 L1
pentamers and for which the crystal structure has been
solved [3-5].
L1 VLP formation requires inter-capsomeric hydrophobic
interactions involving helices 2, 3, and 4 (h2, h3, and h4,
respectively) near the carboxy-terminus of each L1 mono-
mer [3,5,6]. In L1 capsomeres, these helices project later-
ally and outwards onto the solvent-exposed surface. Helix
4 from a L1 monomer within a capsomere forms hydro-
phobic interactions with h2 and h3 of a L1 molecule of an
adjacent capsomere to link the two L1 pentamers. Dele-
tion of h4 has no obvious effect on L1 capsomere assem-
bly, but abolishes the ability of L1 to form T = 1 or T = 7
VLPs [6].
In addition to its self-assembling capabilities, the papillo-
mavirus L1 protein can function as potent immunogens
when oligomerized as capsomeres and VLPs [4,7,8]. Bac-
terially derived L1 proteins from HPV type 16 (HPV-16)
and other HPV serotypes as well as those derived from the
oncogenic canine oral papillomavirus (COPV) form cap-
someres in vitro and elicit neutralizing antibodies [9-12].
Immunization with COPV-L1 capsomeres generates a
protective response in a subsequent COPV-canine oral
mucosal challenge [10]. The L1 HPV VLPs elicit robust
neutralizing and protective antibodies, and have recently
been licensed as prophylactic vaccines against HPV infec-
tion [13,14].
The biophysical and immunological properties of HPV L1
capsomeres and VLPs suggest that these structures may
function as vaccine platforms (reviewed in [15]). To this
end, several studies have described the generation of chi-
meric VLPs bearing heterologous antigenic residues at the
carboxy-terminus or surface-exposed loops of L1 mono-
mers (e.g. [16-18]). However, the challenges of such
approaches include inefficient antigen display, the limited
structural capacity of L1 surface loops to accommodate
foreign epitopes, and potentially significant disruption of
L1 oligomeric structures. To circumvent these issues, we
chose the L1 h4 domain as a novel antigen presentation
site since this region is predicted to be surface-exposed in
capsomeres. In place of the h4 and surrounding residues,
we generated L1 derivatives bearing one of two previously
characterized neutralizing epitopes of the RSV F protein
[19]. We demonstrate that L1 derivatives bearing either of
the two foreign epitopes can form oligomers that are mor-
phologically similar to capsomeres. Furthermore, such
modified L1 pentamers can elicit antibodies that recog-
nize the RSV F protein.
Results
Expression and purification of HPV 16L1 derivatives 
bearing h4 deletion and substitutions
To identify h4-spanning portions of the L1 carboxy termi-
nus region into which heterologous epitopes can be engi-
neered, we first generated two deletions within L1: one
that abolished all but the first residue of h4 (aa 413–430;
termed B-1) and another that deleted h4 and additional
surrounding residues, including the prolines flanking
both sides of h4 (aa 404–436; C-1, Figure 1). HPV type 16
L1 protein and its cognate cDNA were used for all L1
derivatives in this study [20]. Into each of the L1 dele-
tions, we placed two epitopes from the RSV A2 strain F
protein: aa 255–278, which forms a helix-coil-helix struc-
ture in solution and is recognized by the neutralizing,
fusion-inhibiting monoclonal antibody (mAb) L4 [21-
23]; and aa 423–436, a linear epitope recognized by mAb
101 [24,25]. For each of the L1 deletions and its two RSV
F epitope-bearing derivatives, baculoviruses programmed
to express each protein was generated and used to infect
Trichoplusia ni (T. ni) cells. Using isopycnic and sucrose
cushion centrifugations, the resulting capsomere-
enriched fractions were collected, dialyzed into high-salt
buffer (PBS/1 M NaCl for long-term structural stability),
and analyzed for protein yield and purity. We consistently
observed that B-1 capsomeres and its two RSV epitope-
bearing derivatives were of inferior quality and quantity
and thus were not studied further (data not shown). In
contrast, C-1 and its derivatives, 3-1 (bearing RSV F resi-
dues 255–278), and 423-3 (+ RSV F 423–436) were well
expressed (schematically depicted in Figure 2A), enriched
to > 80% purity (data not shown) and were used in sub-
sequent experiments.
Immunological and structural characterization of L1 
derivatives
To determine whether the capsomere derivatives bore the
expected L1 and RSV F-derived epitopes, we subjected the
capsomere preparations to a series of immunological
tests. In ELISAs, control L1 VLPs and all three capsomeres
were recognized by a mouse polyclonal anti-L1 VLP
antiserum as well as anti-HPV 16L1 mAb V5, which recog-
nizes an immunodominant epitope within 16L1 (Figure
2B and 2C) [20,26]. Interestingly, as compared to L1
VLPs, all three capsomere derivatives were recognized
more strongly by mAb V5. In immunoblots, the L1 deriv-
atives were recognized by the CAMVIR-1 anti-HPV 16L1
mAb, with the C-1 deletion migrating slightly faster asVirology Journal 2009, 6:81 http://www.virologyj.com/content/6/1/81
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anticipated and as compared to the L1 from VLPs or the 3-
1 and 423-3 derivatives (Figure 2D). When tested for the
presence of RSV F 255–278, the anti-RSV F mAb L4 recog-
nized 3-1 but not C-1 or 423-3 in immunoblots (Figure
2D) or ELISAs (data not shown). The unavailability of an
anti-RSV F mAb recognizing the second RSV F epitope (aa
423–436) within our antibody panel precluded similar
analysis of 423-3. However, we were able to reproducibly
detect the presence of 423-3 rabbit polyclonal anti-RSV F
antisera (Figure 2D) [23]. Thus we conclude that all cap-
somere derivatives in this study exhibit no gross deficien-
cies in L1-derived epitopes, and that two L1 derivatives
express the RSV F epitopes as expected. In addition, the
ELISA data using V5 mAb suggest that the V5 binding site
may be more readily accessible in capsomeres than in
VLPs and that deletions and substitutions of L1 h4 may
subtly affect accessibility and/or conformation of the V5
recognition site.
To examine the structure of capsomeres and to test its
behavior in solution, we performed transmission electron
microscopy (EM) and sucrose gradient analysis. All three
capsomere preparations formed ring-like structures with
diameters typically ranging from 7–10 nm, consistent
with the morphology previously described for L1 cap-
someres derived from VLPs (Figure 3) [27,28]. We occa-
sionally noted that some capsomere preparations,
especially those for 3-1, appeared to yield structures in
variable states of aggregation (Figure 3, panel 3). This
observation may have been due to either artifacts of EM
sample preparation or our use of PBS/1 M NaCl in antici-
pation of subsequent mouse immunogenicity studies
The h4 domain of the HPV 16L1 monomer Figure 1
The h4 domain of the HPV 16L1 monomer. Shown is a ribbon diagram of the HPV 16L1 monomer that is visualized using 
the Cn3D program (NIH) and arranged such that the h4 domain is shown protruding out of the plane of the diagram. Shown 
below the schematic is the aa sequence of L1 h4 and its surrounding residues 401 – 439; those comprising h4 are highlighted by 
an upper bar over sequence, while aa 404–436 are underlined; the cognate portion within the ribbon diagram are highlighted in 
yellow.Virology Journal 2009, 6:81 http://www.virologyj.com/content/6/1/81
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instead of buffers with lower pH (5–6) that favor cap-
somere formation [6]. Nonetheless, to ensure that the
capsomere derivatives did not exist in primarily aggre-
gated forms, we subjected our preparations to sucrose gra-
dient ultracentrifugation. Using 5 – 20% sucrose gradients
in PBS/1 M NaCl, we noted that the purified 16L1 VLPs
pelleted at the bottom of the gradient, while the sedimen-
tation peak for all three capsomeres was approximately
11S; these observations are in accord with previously
reported fractionations of L1 VLPs and of native cap-
someres under similar centrifugation conditions, respec-
tively (Figure 4) [28]. We also observed limited amounts
of capsomeres disassembled into L1 monomers (which
would remain near the top of the gradient; Figure 4, bot-
tom panel). Moreover, in gradient fractionations of 3-1
and C-1 (to a lesser degree), the capsomeres were local-
ized in fractions with sedimentation coefficients > 11S
(Figure 4, middle panel), presumably due to aggregation
and consistent with EM analysis. Taken together, these
biophysical characterizations suggest that the morphol-
Immunological and structural analyses of the L1 deletion and its derivatives Figure 2
Immunological and structural analyses of the L1 deletion and its derivatives. A) Schematic diagram of the full-length 
16 L1 protein (VLP) and three L1 derivatives: a deletion lacking residues 404–436 (C-1), and those bearing RSV F aa 255–278 
(3-1) and 423–436 (423-3) within the C-1 deletion. B and C) ELISA analysis of L1 derivatives: mouse polyclonal anti-HPV 16 
VLP (Panel B; starting at 1:10,000) and mouse mAb V5 (Panel C; starting at 1:100,000) were used to detect L1 VLPs and the 
capsomere derivatives. Horizontal axis represents serial two-fold dilutions of antibodies and vertical axis represents OD405 nm 
of the resulting reactions. D) Immunoblots of L1 VLP and capsomere derivatives. Except for the 423-3 lane in the right panel, 
~0.5 μg/lane of L1 proteins were resolved on 10%/5% (left and right panels) or 12%/6% (middle panel) SDS-PAGE gels, trans-
ferred onto nitrocellulose, and detected with anti-16L1 mAb (CAMVIR-1;1:60,000 dilution), anti-RSV F neutralizing mAb (L4; 
1:5,000 dilution), or anti-RSV F polyclonal rabbit serum (1:1,000 dilution) followed by either goat anti-mouse IgG-HRP or anti-
rabbit IgG-HRP (at 1:20,000 dilution) and chemiluminescence. Molecular weight standards are shown to the left of each marker 
ladder. The two anti-RSV F antibodies used in this study recognize both the 50 kD and 20 kD subunits of F protein. Compared 
to other lanes, 3–4 fold more total protein of the 423-3 derivative was loaded; similar over-loading of C-1 preparations did not 
lead to increased non-specific recognition of capsomeres by the polyclonal anti-RSV serum (data not shown). The multiple L1 
bands around 55 kD likely indicate minor differences in post-translational modifications of the L1 derivatives.Virology Journal 2009, 6:81 http://www.virologyj.com/content/6/1/81
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ogy and in-solution behavior of the three capsomere
derivatives are similar to those of native L1 pentamers,
although some aggregation appears to occur in a subset of
capsomere preparations.
Immunogenicity of HPV 16L1 derivatives
To determine whether C-1 capsomeres as well as the two
derivatives bearing RSV F epitopes are immunogenic, we
injected BALB/c mice with each of the three capsomere
preparations emulsified with Freund's complete adjuvant
(priming administration) and with Freund's incomplete
adjuvant three weeks later (boosting administration);
control mice were immunized on the same schedule with
unadjuvanted L1 VLPs. Consistent with previous observa-
tions, week 6 sera from these mice exhibited robust
immune response against L1 VLPs in ELISAs (Figure 5)
and immunoblots (data not shown) [7,29]. As compared
to the VLP-injected mouse sera, the slightly reduced VLP
reactivity of sera from capsomere-injected mice may rep-
resent reduced immunogenicity of capsomeres as com-
pared to capsids as previously described [12]. However,
there was no obvious correlation between the anti-L1
immunoreactivity and the presence or absence of RSV F
epitope within the h4 domain. With respect to reac-
togenicity against RSV F protein, sera from mice injected
with 3-1 capsomeres and those immunized with 423-3
capsomeres recognized purified RSV F protein, whereas
sera from C-1 injected mice bore no detectable anti-RSV F
activity (Figure 5). However, none of the immune sera
from capsomere-immunized mice recognized purified
RSV F protein in ELISAs or bore RSV neutralizing activity
(data not shown).
Discussion
Because papillomavirus L1 protein-based oligomers (cap-
someres and VLPs) can elicit a broad array of immune
responses, they have been studied as potential vaccine
platforms (reviewed in [15]). Such efforts have primarily
focused on placing heterologous epitopes on surface-dis-
played, genetically variable loops of L1 or at the carboxy-
terminus of full-length or truncated L1. Since capsomeres
are also immunogenic, we tested the hypothesis that the
h4 domain of the L1 monomer, which projects laterally
and outwards on L1 pentamers, can be used for antigenic
display of foreign epitopes. We demonstrate that: 1) such
antigen presentation is feasible and does not overtly affect
the formation of capsomeres; 2) such capsomeres likely
exists as monomeric capsomeres with some degree of
aggregation noted; and 3) mice immunized with cap-
someres bearing RSV F epitopes generate antisera that rec-
ognizes the purified F protein. Thus, we conclude that
foreign epitopes embedded within the h4 domain can be
immunogenic when presented in the context of cap-
someres.
Our findings have implications for structure of cap-
someres. Two bacterially derived internal deletions span-
ning h4 – residues 410–427 and 404–436 that maintain
or delete the h4-flanking prolines, respectively – can form
capsomeres in vitro [6]. Based on these results, we initially
produced similar deletions for our experiments. Unex-
pectedly, we noted that multiple efforts to purify B-1
(lacking 413–430 and bearing h4 flanking prolines) and
its derivatives bearing the two RSV F epitopes consistently
yielded capsomere preparations of limited quality and
Electron micrographs of L1 capsomere derivatives Figure 3
Electron micrographs of L1 capsomere derivatives. Purified proteins were placed on carbon-copper grids, treated with 
uranyl acetate, and visualized using transmission electron microscopy. The samples are: full-length L1 capsomeres generated 
from dithiothreitol treatment of purified L1 VLPs (Panel 1); C-1 (2); 3-1 (3); and 423-3 (4). The bar in Panel 1 represents the 
scale of the microscopy images.
1                         2                          3           4Virology Journal 2009, 6:81 http://www.virologyj.com/content/6/1/81
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quantity. There are several possible explanations for this
observation, including: subtle differences in the
sequences deleted in our experiments as compared to
those used by others; the use of baculovirus-derived L1
instead of prokaryotically expressed proteins; and struc-
tural constraints induced by the juxtaposition of several
proline residues following internal h4 deletion.
In contrast, the deletion of the entire h4 domain and the
surrounding proline residues (C-1, aa 404–436) led to
purification and enrichment of capsomere derivatives,
which were used in subsequent experiments. Further-
more, this L1 derivative formed capsomeres in the pres-
ence of two different heterologous epitopes of varying
length and predicted structures (RSV F 255–278: helix-
coil-helix 24 aa vs. RSV F 423–436: linear 14 aa). Since h4
projects laterally and outwards from capsomeres, its loca-
tion may be more permissive to aa insertions as compared
to other regions of L1. However, we did note a limited
degree of capsomere aggregation in EM and sucrose gradi-
ent analyses. Such inter-capsomeric interactions may be
dependent on the size and the primary and secondary
structures of the foreign epitope within the h4 domain.
Aggregation of capsomeres, if any, did not appear to affect
the immunogenicity with respect to L1 epitopes.
Immunization of mice with capsomeres bearing RSV F
epitopes elicited anti-F antibodies as tested by immunob-
lots using purified F protein. However, these antisera did
not recognize purified RSV F on ELISAs and were non-
neutralizing (data not shown). Since bacterially derived
RSV F 255–278 fused to the carboxy-terminus of cholera
holotoxin was immunogenic and protective, it is possible
that the embedded presentation of the epitopes within the
Sucrose gradient analysis of L1 VLPs and capsomere derivatives Figure 4
Sucrose gradient analysis of L1 VLPs and capsomere derivatives. Ultracentifugation with 5–20% sucrose gradient in 
PBS/1 M NaCl was used to resolve purified L1 VLPs (top panel), 3-1 (middle panel), and 423-3 (lower panel). For each fraction, 
12 μl was resolved on 10%/5% SDS-PAGE, transferred onto nitrocellulose, and visualized using CAMVIR-1 anti-L1 mAb 
(1:60,000 dilution), goat anti-mouse IgG-HRP conjugate (1:20,000 dilution) and chemiluminescence. Molecular weights are 
shown to the left of the standard ladder. For each fractionation, sedimentation standards were concurrently resolved (bovine 
serum albumin, 4.6S; bovine catalase, 11.3S, and E. coli β-galactosidase, 19S). For the first two standards, the peak fractions for 
each gradient are shown on top of the panel; under our typical ultracentrifugation parameters (16–20 hours) and buffer com-
position with PBS/1 M NaCl as the sucrose solvent, we consistently observed that the 19S standard migrated to the bottom of 
the tube into the pellet (P) fraction. Note that the VLPs are found in the pellet fraction while the capsomere preparations were 
resolved across the gradient (see Results). Note also that there is an 80 kD band that is enriched around the 4.6S standard-
containing fractions in all of our sucrose gradient-derived immunoblots (this Figure and data not shown). Since this band was 
not seen in immunoblots of pre-gradient L1 preparations, we assume that this represents an artifact from one or more of the 
sedimentation standards.Virology Journal 2009, 6:81 http://www.virologyj.com/content/6/1/81
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Immunogenicity of L1 capsomere derivatives Figure 5
Immunogenicity of L1 capsomere derivatives. A) ELISA of L1 VLPs using antisera from mice immunized with L1 VLPs, or 
the capsomere derivatives 3-1, C-1 and 423-3. Horizontal axis represents serial two-fold dilutions starting at 1:5,000 and verti-
cal axis represents OD405 nm of the resulting reactions. B) Immunoblot of purified RSV F protein using antisera from mice 
immunized with 3-1, C-1, or 423-3 (labelled on top of corresponding immunoblot lanes). Equal amounts of RSV F protein 
(approximately 0.5 μg/lane) were resolved on 10%/5% SDS-PAGE gels, transferred onto nitrocellulose, and detected with vari-
ous mouse antisera (1:1,000 dilution) followed by goat anti-mouse IgG-HRP conjugate (1:10,000 dilution) and chemilumines-
cence. The sizes of the molecular weight standards are shown to the left of each marker ladder.Virology Journal 2009, 6:81 http://www.virologyj.com/content/6/1/81
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h4 domain may have altered the anti-F antibody response.
We also cannot exclude the possibility that capsomere
aggregation influenced the anti-RSV F response or that the
immune response against RSV F sequences may have been
subdominant to those on L1 surface loops. Lastly, the
antigen processing and presentation may have been
affected by the use of Freund's adjuvants.
Conclusion
Our results serve as "proof-of-principle" studies to dem-
onstrate that the h4 loop region of L1 can function as an
antigen display site in the context of L1 capsomeres.
Efforts to generate capsomere derivatives in prokaryotic
systems, refine and improve the immunogenicity of mod-
ified L1 oligomers, and to expand the array of antigens for
display, are in progress.
Methods
DNA constructions and manipulations
Plasmids and baculovirus stocks bearing HPV 16L1 cDNA
have previously been described. Deletions of 16L1 cDNA
were created by first ligating the entire cDNA of 16L1 into
the BglII-SmaI site of pSP72 (Promega) to generate pSS1.
Using PCR SuperMix High Fidelity (Invitrogen) and pSS1,
inverse PCR was used to generate 16L1 derivatives deleted
for aa 404–436 (del1) and aa 413–430 (del2). To enable
modular oligonucleotide-based constructions, a unique
NheI site encoding the residues ...AS... was engineered in
place of each of the deletions. The following oligonucle-
otide 5' and 3' pairs (with the NheI site underlined) were
used in PCR amplifications: del1: 5'GGCCGCTAGCAAA-
GAAGATCCCCTTAAAAAATATACTT; and
5'GGCCGCTAGCATTCCAGTCCTCCAAAATAGT; del2:
5'GGCCGCTAGCCATACACCTCCAGCACCTAAAGAA-
GATC; and 5'GGCCGCTAGCGCCTCCTGGAGGAGGTT-
GTAAAC. The following PCR conditions were used: 94°C
× 5 minutes × 1, then 35 cycles of 94°C × 1 minute, 55°C
× 30 seconds, and 68°C × 5 minutes, followed by 68°C ×
7 minutes and overnight storage at 4°C. The PCR ampli-
cons were column purified (Qiagen), serially digested
with NheI and DpnI (to remove the pSS1 template) and
then self-ligated. The resulting plasmids were sequenced
to confirm the existence of the respective deletions and
NheI sites within the L1 cDNA. Thereafter, the modified
L1 cDNAs were excised and ligated into the BglII-SmaI
sites of pVL1392 (Orbigen), during which the NheI site
remained unique within the resulting plasmids, termed
pC-1 (bearing 16L1 del1) and pB-1 (bearing 16L1 del2).
To embed RSV F protein epitopes within the h4 domain
of L1 derivatives, codon-optimized complementary oligo-
nucleotides that encode aa 255–278 (SELLSLINDMPIT-
NDQKKLMSNNV) and 423–438 (TASNKNRGIIKTFS) of
RSV A2 strain F protein (GI: 333933) were used. These oli-
gos bore NheI-compatible termini and were phosphor-
ylated with T4 kinase (NEB), annealed, and ligated into
the NheI site of pC-1 and pB-1. Sequencing of the result-
ing plasmids confirmed the existence of the appropriate
oligonucleotide sequences and predicted to encode the aa
sequence: AS...RSV F epitope...AS, in which the alanine
and serine flanking the RSV-derived residues are derived
from the NheI site. Note that the oligos were designed
such that the first residue (S) of RSV F 255–278 starts from
the serine incorporated from the NheI site, i.e. the amino
terminus of the epitope-bearing sequence is: ...ASELL...
To construct the baculovirus stocks for expression of L1
proteins used in this study, pC-1 and pB-1 derivatives
were co-transfected into Spodoptera frugiperda (Sf9; Invitro-
gen) cells with linearized baculovirus DNA (Baculo-Gold;
BD Biosciences) and cellfectin (Invitrogen). After 72 hrs,
the Sf9 serum-free media from each co-transfection was
removed and the baculovirus stocks were serially propa-
gated and plaque purified × 3 prior to use in T. ni cells.
Protein expression and purification
RSV F protein was purified as previously described. Infec-
tion of T. ni cells with baculovirus bearing the 16L1 cDNA
and subsequent purification of L1 VLPs were performed as
described. The purification of capsomere derivatives was
based on previous protocols and is briefly described as
follows. T.ni cells growing at log phase in 250 mL cultures
(1 – 2 × 106 cells/mL) in serum free media (Express Five,
Invitrogen) were infected with each of the appropriate
baculovirus stocks at a multiplicity of infection (MOI) of
≥ 3. After 72 hrs, the cells were collected by centrifugation,
resuspended in ice-cold PBS + Complete Protease Inhibi-
tor cocktail (Roche), and lysed using a Dounce homoge-
nizer × 20 strokes and and a sonicator (3 × 20–30 second
bursts, continuous cycle, output 3–4). The resulting mix-
ture was brought to 40% CsCl (Roche) in 1× PBS and sub-
jected to isopycnic ultracentrifugation at 28,000 × rpm ×
40 hrs at 4°C using a Beckman SW28.1Ti rotor. The visi-
ble L1 band within the CsCl gradient was removed, dia-
lyzed against PBS/0.5 M NaCl for >1 hr, and then
overlayed onto a 30%/63% sucrose cushion using PBS/
0.5 M NaCl as the solvent. After centrifugation at 28,000
× rpm × 5 hr at 4°C in a SW28.1Ti rotor, the capsomere-
enriched fraction at the 0%/30% sucrose interface was
removed and dialyzed exhaustively against PBS/1 M NaCl
prior to -80°C storage and subsequent analysis.
Immunological and structural characterizations of 
capsomere derivatives
For protein gel electrophoresis, capsomeres and L1 VLPs
were mixed 1:1 with 2× SDS-sample buffer containing β-
mercaptoethanol, heated at 95°C for 2–5 minutes, and
then resolved on 10%/5% discontinuous SDS-PAGE
using BioRad Protean Tetra-cell apparatus. Where appro-
priate, molecular weight markers (Novex and MagicMark;Virology Journal 2009, 6:81 http://www.virologyj.com/content/6/1/81
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Invitrogen) were resolved in parallel and proteins were
visualized by staining with Coomassie Brilliant Blue R-
250. For immunoblots, the proteins were resolved on
SDS-PAGE as above and then transferred onto nitrocellu-
lose using a BioRad Trans-blot device (typically at 100V at
room temperature for 1 hr). PBS + 0.1% Tween-20 (PBST)
+ 2% dried non-fat milk was used to block non-specific
protein binding onto nitrocellulose. For detection of L1
protein, CAMVIR-1 (Santa Cruz Biotechnology) was used
at 1:60,000 dilution followed by goat anti-mouse IgG
heavy/light chain antibody-horseradish peroxidase (HRP)
conjugate (Southern Biotech) at 1:20,000 in PBST. Anti-
body-antigen complexes were visualized by chemilumi-
nescence (ECL; Pierce) and radiography (Kodak).
ELISAs were performed essentially as previously
described. Typically, each protein for analysis was diluted
with PBS and plated at 100 ng/well onto 96 well ELISA
plates (Nunc) and incubated overnight at 4°C. Following
incubation with primary antibodies as described in figure
legends, alkaline phosphatase-conjugated goat anti-
mouse secondary antibodies (Southern Biotech) and
phosphatase substrate tablets (Sigma-Aldrich) were then
used to visualize antigen-antibody complexes. The result-
ing colorimetric reactions were read at OD405 nm using a
96-well ELISA plate reader (Molecular Devices).
For electron microscopy analysis, capsomere samples
(typically at 0.5–1 mg/ml in PBS/1 M NaCl) were diluted
1:10 in ice-cold PBS/1 M NaCl and then adsorbed onto
carbon-coated grid for approximately 1 – 3 minutes.
Excess fluid was then blotted with filter paper and the
grids were negatively stained with 2% uranyl acetate.
Images from grids were obtained using a Hitachi 7100
transmission electron microscope at 80 kV and 60,000 ×
– 100,000 × magnification. As control images for cap-
someres, intact 16L1 VLPs were dissociated into cap-
someres using previously described incubation
conditions with dithiothreitol.
Sucrose gradients with standards (bovine catalase and E.
coli  β-galactosidase, Sigma-Aldrich; bovine serum albu-
min, VWR) were performed as described except that PBS/
1 M NaCl was used as the sucrose solvent. Approximately
50 – 100 μg of each of the three standards were mixed
with 100 μg of each of the capsomeres or intact L1 VLPs
and subjected to ultracentrifugation at 41,000 × rpm × 16
– 20 hours at 4°C using a SW41.1Ti rotor (Beckman). The
resulting gradient fractions (0.5 ml aliquots) were serially
collected from the top of the ultracentrifuge tube, resolved
on 10/5% SDS-PAGE, and then stained with Coomassie
Brilliant Blue R-250 (for localization of standard peaks) or
transferred to nitrocellulose and probed with CAMVIR-1
anti-L1 mAb prior to chemiluminescence detection.
Immunogenicity of capsomere derivatives in mice
The animals were fed standard diet and water ad libitum
and housed a pathogen-free environment within the Uni-
versity of Rochester School of Medicine and Dentistry
Vivarium. Prior to any immunogenicity studies, all animal
care and use protocols used in this study were approved
by the Institutional Animal Care and Use Committee at
the University of Rochester Medical Center. Female 6 – 8
week old BALB/c mice (Jackson Laboratories) in groups of
4 – 5 mice per capsomere were injected intramuscularly
with 50 ug of each of the capsomeres. For priming injec-
tion, the capsomeres were diluted 1:1 and emulsified with
Freund's complete adjuvant, while for boosts at weeks 3
and 6, Freund's incomplete adjuvant was used at 1:1 dilu-
tion. At week 6, submandibular bleeds were performed on
the mice and the resulting sera were analyzed for reac-
togenicity against purified RSV F protein and purifed 16L1
VLPs. For antisera against 16L1 VLPs, 50 μg of purified
VLPs were injected intramuscularly into mice as above
except that no adjuvants were used.
Competing interests
YM, RCR, and EEW are authors of a provisional patent
application on the use of human papillomavirus L1 pro-
tein and its derivatives, including capsomeres, as RSV vac-
cine candidates.
Authors' contributions
YM designed the experiments and drafted the manuscript.
YM and PML performed all experiments except for purifi-
cation of RSV F protein and RSV neutralization assays that
were performed by EEW. RCR provided DNA for construc-
tions and offered advice on capsomere purification and
characterization. All authors read and approved the final
manuscript.
Acknowledgements
This work was supported by the NIH (R21 AI076781-02) as well as the 
2007-8 Buswell Fellowship Award (Department of Medicine, University of 
Rochester School of Medicine and Dentristry) to YM. We thank Karen 
Bentley (University of Rochester Medical Center Electron Microscopy 
Core Director) for EM photographys and for helpful discussions.
References
1. zur Hausen H, Gissmann L: Lymphotropic papovaviruses iso-
lated from African green monkey and human cells.  Med
Microbiol Immunol (Berl) 1979, 167(3):137-153.
2. Rose RC, Bonnez W, Reichman RC, Garcea RL: Expression of
human papillomavirus type 11 L1 protein in insect cells: in
vivo and in vitro assembly of viruslike particles.  J Virol 1993,
67(4):1936-1944.
3. Modis Y, Trus BL, Harrison SC: Atomic model of the papilloma-
virus capsid.  EMBO J 2002, 21(18):4754-4762.
4. Chen XS, Casini G, Harrison SC, Garcea RL: Papillomavirus capsid
protein expression in Escherichia coli: purification and
assembly of HPV11 and HPV16 L1.  J Mol Biol 2001,
307(1):173-182.
5. Chen XS, Garcea RL, Goldberg I, Casini G, Harrison SC: Structure
of small virus-like particles assembled from the L1 protein of
human papillomavirus 16.  Mol Cell 2000, 5(3):557-567.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Virology Journal 2009, 6:81 http://www.virologyj.com/content/6/1/81
Page 10 of 10
(page number not for citation purposes)
6. Bishop B, Dasgupta J, Chen XS: Structure-based engineering of
papillomavirus major capsid l1: controlling particle assem-
bly.  Virol J 2007, 4:3.
7. Rose RC, White WI, Li M, Suzich JA, Lane C, Garcea RL: Human
papillomavirus type 11 recombinant L1 capsomeres induce
virus-neutralizing antibodies.  J Virol 1998, 72(7):6151-6154.
8. Evans TG, Bonnez W, Rose RC, Koenig S, Demeter L, Suzich JA,
O'Brien D, Campbell M, White WI, Balsley J, Reichman RC: A Phase
1 study of a recombinant viruslike particle vaccine against
human papillomavirus type 11 in healthy adult volunteers.  J
Infect Dis 2001, 183(10):1485-1493.
9. Rose RC, White WI, Li M, Suzich JA, Lane C, Garcea RL: Human
papillomavirus type 11 recombinant L1 capsomeres induce
virus-neutralizing antibodies.  J Virol 1998, 72(7):6151-6154.
10. Yuan H, Estes PA, Chen Y, Newsome J, Olcese VA, Garcea RL, Sch-
legel R: Immunization with a pentameric L1 fusion protein
protects against papillomavirus infection.  J Virol 2001,
75(17):7848-7853.
11. Fligge C, Giroglou T, Streeck RE, Sapp M: Induction of type-spe-
cific neutralizing antibodies by capsomeres of human papil-
lomavirus type 33.  Virology 2001, 283(2):353-357.
12. Thones N, Herreiner A, Schadlich L, Piuko K, Muller M: A direct
comparison of human papillomavirus type 16 L1 particles
reveals a lower immunogenicity of capsomeres than virus-
like particles with respect to the induced antibody response.
J Virol 2008, 82(11):5472-5485.
13. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB,
Chiacchierini LM, Jansen KU, Proof of Principle Study Investigators: A
controlled trial of a human papillomavirus type 16 vaccine.  N
Engl J Med 2002, 347(21):1645-1651.
14. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM,
Leodolter S, Tang GW, Ferris DG, Steben M, Bryan J, Taddeo FJ,
Railkar R, Esser MT, Sings HL, Nelson M, Boslego J, Sattler C, Barr E,
Koutsky LA, Females United to Unilaterally Reduce Endo/Ectocervical
Disease (FUTURE) I Investigators: Quadrivalent vaccine against
human papillomavirus to prevent anogenital diseases.  N Engl
J Med 2007, 356(19):1928-1943.
15. Chackerian B: Virus-like particles: flexible platforms for vac-
cine development.  Expert Rev Vaccines 2007, 6(3):381-390.
16. Chackerian B, Lowy DR, Schiller JT: Induction of autoantibodies
to mouse CCR5 with recombinant papillomavirus particles.
Proc Natl Acad Sci USA 1999, 96(5):2373-2378.
17. Slupetzky K, Shafti-Keramat S, Lenz P, Brandt S, Grassauer A, Sara M,
Kirnbauer R: Chimeric papillomavirus-like particles express-
ing a foreign epitope on capsid surface loops.  J Gen Virol 2001,
82(Pt 11):2799-2804.
18. Varsani A, Williamson AL, de Villiers D, Becker I, Christensen ND,
Rybicki EP: Chimeric human papillomavirus type 16 (HPV-16)
L1 particles presenting the common neutralizing epitope for
the L2 minor capsid protein of HPV-6 and HPV-16.  J Virol
2003, 77(15):8386-8393.
19. Walsh EE, Hruska J: Monoclonal antibodies to respiratory syn-
cytial virus proteins: identification of the fusion protein.  J Virol
1983, 47(1):171-177.
20. Rose RC, Bonnez W, Da Rin C, McCance DJ, Reichman RC: Sero-
logical differentiation of human papillomavirus types 11, 16
and 18 using recombinant virus-like particles.  J Gen Virol 1994,
75(Pt 9):2445-2449.
21. Lopez JA, Bustos R, Orvell C, Berois M, Arbiza J, Garcia-Barreno B,
Melero JA: Antigenic structure of human respiratory syncytial
virus fusion glycoprotein.  J Virol 1998, 72(8):6922-6928.
22. Toiron C, Lopez JA, Rivas G, Andreu D, Melero JA, Bruix M: Con-
formational studies of a short linear peptide corresponding
to a major conserved neutralizing epitope of human respira-
tory syncytial virus fusion glycoprotein.  Biopolymers 1996,
39(4):537-548.
23. Walsh EE, Cote PJ, Fernie BF, Schlesinger JJ, Brandriss MW: Analysis
of the respiratory syncytial virus fusion protein using mono-
clonal and polyclonal antibodies.  J Gen Virol 1986, 67(Pt
3):505-513.
24. Arbiza J, Taylor G, Lopez JA, Furze J, Wyld S, Whyte P, Stott EJ,
Wertz G, Sullender W, Trudel M: Characterization of two anti-
genic sites recognized by neutralizing monoclonal antibodies
directed against the fusion glycoprotein of human respira-
tory syncytial virus.  J Gen Virol 1992, 73(Pt 9):2225-2234.
25. Wu SJ, Schmidt A, Beil EJ, Day ND, Branigan PJ, Liu C, Gutshall LL,
Palomo C, Furze J, Taylor G, Melero JA, Tsui P, Del Vecchio AM,
Kruszynski M: Characterization of the epitope for anti-human
respiratory syncytial virus F protein monoclonal antibody
101F using synthetic peptides and genetic approaches.  J Gen
Virol 2007, 88(Pt 10):2719-2723.
26. Ryding J, Dahlberg L, Wallen-Ohman M, Dillner J: Deletion of a
major neutralizing epitope of human papillomavirus type 16
virus-like particles.  J Gen Virol 2007, 88(Pt 3):792-802.
27. Li M, Cripe TP, Estes PA, Lyon MK, Rose RC, Garcea RL: Expression
of the human papillomavirus type 11 L1 capsid protein in
Escherichia coli: characterization of protein domains
involved in DNA binding and capsid assembly.  J Virol 1997,
71(4):2988-2995.
28. McCarthy MP, White WI, Palmer-Hill F, Koenig S, Suzich JA: Quan-
titative disassembly and reassembly of human papillomavi-
rus type 11 viruslike particles in vitro.  J Virol 1998, 72(1):32-41.
29. Rose RC, Bonnez W, Strike DG, Reichman RC: Expression of the
full-length products of the human papillomavirus type 6b
(HPV-6b) and HPV-11 L2 open reading frames by recom-
binant baculovirus, and antigenic comparisons with HPV-11
whole virus particles.  J Gen Virol 1990, 71(Pt 11):2725-2729.